Compare Badger Meter Inc (BMI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Badger Meter Inc vs Merck & Co., Inc. — how do they compare? Badger Meter Inc trades at $134.68 (market cap $3.93B), while Merck & Co., Inc. trades at $133.87 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 81.9× Badger Meter Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| BMI | MRK | |
|---|---|---|
Market Cap | $3.93B | $321.77B |
Sector | Technology | Health |
52-Week High | $193.09 | $131.84 |
52-Week Low | $113.41 | $77.60 |
Enterprise Value | $3.84B | $368.53B |
Dividend Yield | 1.18% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Badger Meter (BMI) trades at $133.63, down 2.06% amid bearish technical signals and mixed earnings performance. The stock shows strong profitability with 14.27% net margin and 18.48% ROE, but faces headwinds from recent securities class action lawsuits and declining revenue projections for 2026. Technical indicators suggest bearish momentum with resistance at $137-$139 levels.
While BMI maintains solid fundamentals and analyst consensus targets $155.20 (16% upside), near-term risks include legal uncertainties and earnings volatility. The company's water technology focus provides defensive characteristics, but investors should weigh class action litigation risks against the stock's valuation premium (P/E 31.78).
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
